About KAYOTHERA, INC.
Kayothera is a preclinical therapeutics company specializing in developing first-in-class, small molecule inhibitors of the retinoid nuclear receptor pathway for unmet medical needs, including diabetes, obesity, and cancer.
Development of first-in-class, orally-available small molecule inhibitors of the retinoid and rexinoid nuclear receptor pathwaysTargeting of ALDH1A2 and ALDH1A3 enzymes to block retinoic acid signalingResearch and development of therapies for diabetes, obesity, and cancerCollaboration with academic institutions such as Princeton University and the Ludwig Institute for Cancer Research
Is this your company?
Claim KAYOTHERA, INC. to unlock the federal & state contracts GovIntel's AI has matched to you right now — plus your own scored past-performance, who you're up against, and who's risky to team with.
Claim KAYOTHERA, INC. & see your matchesFree to claim. Takes about a minute.
Data compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate, or want this page removed? Request a correction or removal.